胃癌腹腔灌注化疗临床进展  

Progression for IPC in gastric cancer

作　　者：黄万中[1] 蒋华[1] 

机构地区：[1]蚌埠医学院附属连云港肿瘤医院肿瘤内科,江苏连云港222002

出　　处：《现代肿瘤医学》2010年第2期404-407,共4页Journal of Modern Oncology

基　　金：江苏省卫生厅面上项目基金资助(编号:H200771)

摘　　要：局部复发和转移是导致胃癌患者死亡的最主要原因。近年来,腹腔内化疗(intraperitoneal chemotherapy,IPC)作为进展期胃癌的辅助治疗手段之一已逐渐应用于临床,并取得了很好的疗效。IPC相对于全身化疗有着明显的药代动力学优势,药物是影响其疗效的主要因素。目前IPC常用的药物有5-Fu、PDD、喜树碱等,取得了一定的疗效。近年来有研究显示紫杉类药物更适用于IPC,并在临床取得了独特的疗效。IPC已在临床应用多年,其操作简单、使用安全、方便。本文就晚期胃癌腹腔内化疗的机制、特点及药物的选择和疗效等方面进行综述。Local recurrence and metastasis are the most important causes of death for gastric cancer patients. In the recent years,gastric cancer intraperitoneal chemotherapy（IPC） has become one of the adjuvant therapy and has been widely used in the clinical therapy, and improved the efficient of gastric cancer treatment. IPC has more significant pharmacokinetic advantages than systemic chemotherapy, and the choice of drug is the main affecting factor on efficacy. 5 -Fu, PDD, camptothecin are currently commonly used in intraperitoneal instillation, achieved a certain degree of efficacy. In recent years, studies have shown that taxanes are more applicable to IPC, and achieved unique clinical resuits. IPC has been applicated in clinical for many years,which is easy to operate, safe to use, and convenient. In this article, mechanisms, characteristics, drug selection and effection of IPC for advanced gastric cancer were introduced.

关 键 词：胃癌 腹腔内化疗 紫杉类药物 

分 类 号：R735.2[医药卫生—肿瘤]